Literature DB >> 7483141

Effects and systemic uptake of the new mitomycin C analogue KW-2149 in beagle dogs after intravesical administration.

M Sorber1, E A De Bruijn, M Kockx, J Bultinck, A T Van Oosterom, L Denis.   

Abstract

The present study was designed to evaluate the local effects of the new mitomycin C analogue KW-2149 after intravesical instillation, together with its penetration into the systemic circulation in healthy beagle dogs. Two reference dogs were treated with two instillations of mitomycin C (30 mg in 30 ml phosphate buffer). Four dogs were given two, three, four and six instillations, respectively, of KW-2149 (60 mg in 30 ml phosphate buffer). KW-2149 concentrations measured in the systemic circulation were very low and were frequently found to be below the limit of determination. The number of instillations had no influence on the KW-2149 concentrations measured in the systemic circulation. Blood analysis showed no systemic toxicity. The histopathological findings in the bladder were comparable in both groups. The number of instillations had no influence on the severity of the lesions found in the bladder wall. On the basis of its in vitro activity KW-2149 can be regarded as a promising agent for intravesical treatment of superficial bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7483141     DOI: 10.1007/bf00389567

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  10 in total

1.  Determination of the new anticancer agent KW 2149, 7-N-[2-[2-(gamma-L-glutamylamino)ethyl)dithio)ethyl]mitomycin C, an analogue of mitomycin C.

Authors:  G Pattyn; A T van Oosterom; E A de Bruijn; U R Tjaden
Journal:  J Chromatogr       Date:  1991-03-08

Review 2.  [Which intravesical chemotherapy for what tumor of the bladder?].

Authors:  C Bouffioux; L Denis; K H Kurth; M De Pauw; R Sylvester
Journal:  J Urol (Paris)       Date:  1988

Review 3.  Rationale for intensive intravesical chemotherapy for superficial bladder cancer.

Authors:  M S Soloway
Journal:  J Urol       Date:  1980-04       Impact factor: 7.450

4.  The effect of intravesical instillations of thiotepa, mitomycin C, and adriamycin on normal urothelium: an experimental study in rats.

Authors:  D Friedman; U M Mooppan; Y Rosen; H Kim
Journal:  J Urol       Date:  1991-05       Impact factor: 7.450

5.  Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overview.

Authors:  L Denis; C Bouffioux; K H Kurth; F Debruyne; R Sylvester; M De Pauw
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.

Authors:  M Morimoto; T Ashizawa; H Ohno; M Azuma; E Kobayashi; M Okabe; K Gomi; M Kono; Y Saitoh; Y Kanda
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

7.  Determination of mitomycin C in plasma, serum and urine by high-performance liquid chromatography with ultra-violet and electrochemical detection.

Authors:  U R Tjaden; J P Langenberg; K Ensing; W P van Bennekom; E A de Bruijn; A T van Oosterom
Journal:  J Chromatogr       Date:  1982-11-12

8.  Bladder wall penetration of intravesical mitomycin C in dogs.

Authors:  M G Wientjes; J T Dalton; R A Badalament; J R Drago; J L Au
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

9.  Synthesis and antitumor activity of a novel water soluble mitomycin analog; 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C.

Authors:  M Kono; Y Saitoh; M Kasai; A Sato; K Shirahata; M Morimoto; T Ashizawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1989-04       Impact factor: 1.645

10.  Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.

Authors:  L Y Dirix; E E Gheuens; S van der Heyden; A T van Oosterom; E A De Bruijn
Journal:  Anticancer Drugs       Date:  1994-06       Impact factor: 2.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.